Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Is survivin expression prognostic or predictive in malignant pleural mesothelioma?

Hmeljak J, Erčulj N, Dolžan V, Pižem J, Kern I, Kovač V, Cemažar M, Cör A.

Virchows Arch. 2013 Mar;462(3):315-21. doi: 10.1007/s00428-013-1373-9. Epub 2013 Jan 29.

PMID:
23358691
2.

BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.

Hmeljak J, Erčulj N, Dolžan V, Kern I, Cör A.

J Cancer Res Clin Oncol. 2011 Nov;137(11):1641-51. doi: 10.1007/s00432-011-1030-0. Epub 2011 Aug 23.

PMID:
21861135
3.

Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma.

Kleinberg L, Lie AK, Flørenes VA, Nesland JM, Davidson B.

Hum Pathol. 2007 Jul;38(7):986-94. Epub 2007 Mar 9.

PMID:
17350081
4.

Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T.

Respir Med. 2011 Jan;105(1):137-42. doi: 10.1016/j.rmed.2010.10.010. Epub 2010 Oct 30.

5.

Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.

Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L.

Cancer Res. 2009 Jun 1;69(11):4598-604. doi: 10.1158/0008-5472.CAN-08-4523.

6.

Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.

Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ, Bueno R.

J Pathol. 2007 Mar;211(4):447-54.

PMID:
17253596
7.

Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.

O'Kane SL, Cawkwell L, Campbell A, Lind MJ.

Eur J Cancer. 2005 Jul;41(11):1645-8.

PMID:
15964184
8.

Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.

Lindholm PM, Soini Y, Myllärniemi M, Knuutila S, Heikinheimo M, Kinnula VL, Salmenkivi K.

J Clin Pathol. 2009 Apr;62(4):339-44. doi: 10.1136/jcp.2008.060533. Epub 2008 Dec 5.

PMID:
19060016
9.

Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.

Ismail HM, Nouh MA, Abulkheir IL, Abd El-Rahman Ael-R, Tawfik HN.

J Egypt Natl Canc Inst. 2006 Dec;18(4):303-10.

10.

Prognostic role of osteopontin expression in malignant pleural mesothelioma.

Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV, Papotti M.

Am J Clin Pathol. 2008 Jul;130(1):58-64. doi: 10.1309/TWCQV536WWRNEU51.

PMID:
18550471
11.

Prognostic value of Survivin and Livin in nasopharyngeal carcinoma.

Xiang Y, Yao H, Wang S, Hong M, He J, Cao S, Min H, Song E, Guo X.

Laryngoscope. 2006 Jan;116(1):126-30.

PMID:
16481824
12.

Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma.

Leonardo E, Zanconati F, Bonifacio D, Bonito LD.

Pathol Res Pract. 2001;197(4):253-6.

PMID:
11358011
13.

Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.

Kang Y, Ding M, Tian G, Guo H, Wan Y, Yao Z, Li B, Lin D.

Oncol Rep. 2013 Jul;30(1):313-9. doi: 10.3892/or.2013.2429. Epub 2013 Apr 26.

PMID:
23624653
14.

Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.

Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A.

Int J Oncol. 2001 May;18(5):1093-8.

PMID:
11295061
15.

p27 immunostaining is related to prognosis in malignant mesothelioma.

Beer TW, Shepherd P, Pullinger NC.

Histopathology. 2001 Jun;38(6):535-41.

PMID:
11422497
16.

Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.

Hiraki A, Aoe K, Murakami T, Nakamura Y, Yamazaki K, Sueoka N, Taguchi K, Kamei T, Maeda T, Takeyama H, Kishimoto T, Nishimura M, Sugi K.

Oncol Rep. 2005 Aug;14(2):357-62.

PMID:
16012715
17.

Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.

Park DS, Hwang KE, Shim H, Kim BR, Choi KH, Park SH, Park SD, Jeong ET, Kim HR.

Clin Exp Metastasis. 2012 Feb;29(2):83-9. doi: 10.1007/s10585-011-9431-7. Epub 2011 Nov 2.

PMID:
22045227
18.

p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma.

Bongiovanni M, Cassoni P, De Giuli P, Viberti L, Cappia S, Ivaldi C, Chiusa L, Bussolati G.

Cancer. 2001 Sep 1;92(5):1245-50.

PMID:
11571739
19.

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K.

Lung Cancer. 2008 Aug;61(2):235-43. doi: 10.1016/j.lungcan.2007.12.025. Epub 2008 Feb 20.

PMID:
18281122
20.

Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.

Thylén A, Hjerpe A, Martensson G.

Cancer. 2001 Sep 1;92(5):1224-30.

PMID:
11571736

Supplemental Content

Support Center